Reduction in HER-2 protein expression in a breast tumor HER-2 positive after only one injection of Trastuzumab: a case report
نویسندگان
چکیده
منابع مشابه
Reduction in HER-2 protein expression in a breast tumor HER-2 positive after only one injection of Trastuzumab: a case report
HER-2 is overexpressed in 20 to 30% of breast cancer. Generally, metastases of a breast tumor have the same HER-2 status, although some discordances were reported.We report a case of reduction in HER-2 expression assessed by immunohistochemistry, following one day of a Trastuzumab injection, of a metastatic breast cancer to lymph nodes. Initially, the breast tumor HER-2 status was positive acco...
متن کاملHER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy.
Trastuzumab with a taxane as first-line therapy is now the standard of care for patients with human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer (MBC). The search for additional and more effective trastuzumab-based therapies continues. Novel combinations of trastuzumab with chemotherapeutic agents, including vinorelbine, gemcitabine, and capecitabine, and hormona...
متن کاملHer-2 positive mucinous carcinoma breast cancer, case report
INTRODUCTION Mucinous carcinoma is a variant of invasive breast carcinomas that accounts for 2% of them and has a better prognosis in contrast to the non-specific invasive carcinoma. They regularly are positive for estrogen and progesterone receptors and, generally, they do not overexpress HER2. When HER2 is positive, the first line treatment is trastuzumab; although the resistance is 52-89% fo...
متن کاملHER-3 expression in HER-2-amplified breast carcinoma
AIM OF THE STUDY To determine whether the expression of HER-3 influences the survival of HER-2 positive patients with breast cancer (BC). MATERIAL AND METHODS In the present work, the expression of HER-3 in a group of 35 HER-2 positive patients with BC was studied by performing immunohistochemistry (IHC) in formalin-fixed paraffin embedded tissues. RESULTS Higher HER-3 status if estimated b...
متن کاملAdjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Up to one fourth of women diagnosed with early breast cancer (EBC) have tumors that are human epidermal growth factor receptor 2 (HER-2) positive. This is associated with a high risk of relapse and death from meta-static disease. Trastuzumab, a monoclonal antibody directed against the extracellular domain of HER-2, improves survival and quality of life in women with HER-2-positive metastatic br...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cases Journal
سال: 2009
ISSN: 1757-1626
DOI: 10.4076/1757-1626-2-8099